Epidermal growth factor receptor antagonists companion diagnostics - QIAGEN

Drug Profile

Epidermal growth factor receptor antagonists companion diagnostics - QIAGEN

Alternative Names: Afatinib (Tovok) companion diagnostic - QIAGEN; Afatinib companion diagnostic - QIAGEN; Anti-EGFR companion diagnostic - QIAGEN; Cetuximab (Erbitux) companion diagnostic - QIAGEN; KRAS Gene Mutation Analysis, Colorectal cancer (cetuximab); Panitumumab (Vectibix) companion diagnostic - QIAGEN; therascreen EGFR RGQ PCR Kit (afatinib); Therascreen EGFR test - QIAGEN; therascreen KRAS RGQ PCR Kit (panitumumab); Therascreen KRAS test - QIAGEN

Latest Information Update: 22 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator QIAGEN
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Colorectal cancer; Non-small cell lung cancer

Most Recent Events

  • 23 May 2014 Registered for Non-small cell lung cancer (diagnosis) in China
  • 23 May 2014 US FDA approves therascreen® KRAS RGQ PCR Kit as a companion diagnostic for panitumumab for first-line, combination treatment of metastatic Colorectal cancer in the USA
  • 25 Oct 2013 Launched for Colorectal cancer (diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top